Mohamed Altai
Lund University
BiophysicsMolecular imagingReceptorChemistryConjugateIn vitroIn vivoBiodistributionPretargetingPeptideDOTAProstate cancerAffibody moleculeNuclear medicineRadionuclide therapyMoleculeCancer researchScaffold proteinMonoclonal antibodyBiochemistryMedicine
80Publications
19H-index
845Citations
Publications 79
Newest
#1Amanda Kristiansson (Lund University)H-Index: 5
#2Anders ÖrbomH-Index: 3
Last. Joanna Strand (Lund University)H-Index: 12
view all 11 authors...
Anti-prostate specific membrane antigen (PSMA) radioligand therapy is promising but not curative in castration resistant prostate cancer. One way to broaden the therapeutic index could be to administer higher doses in combination with radioprotectors, since administered radioactivity is kept low today in order to avoid side-effects from a high absorbed dose to healthy tissue. Here, we investigated the human radical scavenger α1-microglobulin (A1M) together with 177-Lutetium (177Lu) labeled PSMA-...
1 CitationsSource
#1Darren R. Veach (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 25
#2Claire M. Storey (UCLA: University of California, Los Angeles)H-Index: 1
Last. David Ulmert (UCLA: University of California, Los Angeles)H-Index: 30
view all 21 authors...
PURPOSE Most prostate cancer (PCa) patients treated with androgen receptor (AR)-signaling inhibitors develop therapeutic resistance due to restoration of AR-functionality. Thus, there is a critical need for novel treatment approaches. Here we investigate the theranostic potential of hu5A10, a humanized monoclonal antibody specifically targeting free prostate-specific antigen (KLK3). EXPERIMENTAL DESIGN LNCaP-AR xenografts (NSG mice) and KLK3_Hi-Myc transgenic mice were imaged with 89Zr- or treat...
1 CitationsSource
#1Javad Garousi (Uppsala University)H-Index: 13
#2Emma von Witting (KTH: Royal Institute of Technology)H-Index: 4
Last. Sophia Hober (KTH: Royal Institute of Technology)H-Index: 41
view all 11 authors...
Abstract Molecular recognition in targeted therapeutics is typically based on immunoglobulins. Development of engineered scaffold proteins (ESPs) has provided additional opportunities for the development of targeted therapies. ESPs offer inexpensive production in prokaryotic hosts, high stability and convenient approaches to modify their biodistribution. In this study, we demonstrated successful modification of the biodistribution of an ESP known as ADAPT (Albumin-binding domain Derived Affinity...
1 CitationsSource
#1Anders Myrhammar (KTH: Royal Institute of Technology)H-Index: 1
#2Anzhelika Vorobyeva (Uppsala University)H-Index: 10
Last. Mohamed Altai (Lund University)H-Index: 19
view all 9 authors...
Radionuclide molecular imaging of cancer-specific targets is a promising method to identify patients for targeted antibody therapy. Radiolabeled full-length antibodies however suffer from slow clearance, resulting in high background radiation. To overcome this problem, a pretargeting system based on complementary peptide nucleic acid (PNA) probes has been investigated. The pretargeting relies on sequential injections of primary, PNA-tagged antibody and secondary, radiolabeled PNA probe, which ar...
Source
#1D. Veach (UCLA: University of California, Los Angeles)
Last. David UlmertH-Index: 30
view all 21 authors...
PurposeMost prostate cancer (PCa) patients treated with androgen receptor (AR)-signaling inhibitors develop therapeutic resistance due to restoration of AR-functionality. Thus, there is a critical need for novel treatment approaches. Here we investigate the theranostic potential of hu5A10, a humanized monoclonal antibody specifically targeting free prostate-specific antigen (KLK3). Experimental DesignLNCaP-AR xenografts (NSG mice) and KLK3_Hi-Myc transgenic mice were imaged with 89Zr- or treated...
Source
#1Charles Dahlsson Leitao (KTH: Royal Institute of Technology)H-Index: 6
#2Sara S. Rinne (Uppsala University)H-Index: 8
Last. Anna Orlova (Uppsala University)H-Index: 53
view all 10 authors...
Human epidermal growth factor receptor 3 (HER3) has been increasingly scrutinized as a potential drug target since the elucidation of its role in mediating tumor growth and acquired therapy resistance. Affibody molecules are so-called scaffold proteins with favorable biophysical properties, such as a small size for improved tissue penetration and extravasation, thermal and chemical stability, and a high tolerance to modifications. Additionally, affibody molecules are efficiently produced in prok...
1 CitationsSource
#1Javad Garousi (Uppsala University)H-Index: 13
#2Anzhelika Vorobyeva (Uppsala University)H-Index: 10
Last. M. Altai (Lund University)H-Index: 2
view all 3 authors...
Affibody molecules are the most studied class of engineered scaffold proteins (ESPs) in radionuclide molecular imaging. Attempts to use affibody molecules directly labelled with radiometals for targeted radionuclide therapy were hampered by the high uptake and retention of radioactivity in kidneys. Several promising strategies have been implemented to circumvent this problem. Here, we investigated whether a pharmacological approach targeting different components of the reabsorption system could ...
2 CitationsSource
#1Anzhelika Vorobyeva (Uppsala University)H-Index: 10
#2E. A. Konovalova (RAS: Russian Academy of Sciences)H-Index: 4
Last. Sergey Deyev (Tomsk Polytechnic University)H-Index: 2
view all 10 authors...
Epithelial cell adhesion molecule (EpCAM) is overexpressed in 55%–75% of ovarian carcinomas (OC). EpCAM might be used as a target for a treatment of disseminated OC. Designed ankyrin repeats protein (DARPin) Ec1 is a small (18 kDa) protein, which binds to EpCAM with subnanomolar affinity. We tested a hypothesis that Ec1 labeled with a non-residualizing label might serve as a companion imaging diagnostic for stratification of patients for EpCAM-targeting therapy. Ec1 was labeled with 125I using N...
3 CitationsSource
#1Joanna StrandH-Index: 12
#2Anders ÖrbomH-Index: 3
Last. Mohamed AltaiH-Index: 19
view all 5 authors...
#1Haozhong Ding (KTH: Royal Institute of Technology)H-Index: 3
#2M. Altai (Lund University)H-Index: 2
Last. Torbjörn Gräslund (KTH: Royal Institute of Technology)H-Index: 21
view all 11 authors...
The human epidermal growth factor receptor 2 (HER2) is a clinically validated target for cancer therapy, and targeted therapies are often used in regimens for patients with a high HER2 expression level. Despite the success of current drugs, a number of patients succumb to their disease, which motivates development of novel drugs with other modes of action. We have previously shown that an albumin binding domain-derived affinity protein with specific affinity for HER2, ADAPT6, can be used to deli...
Source